{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T02:57:51Z","timestamp":1774321071472,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.soncn.2024.151621","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T20:01:10Z","timestamp":1712692870000},"page":"151621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nursing Considerations for Cytokine Release Syndrome in Relapsed\/Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study"],"prefix":"10.1016","volume":"40","author":[{"given":"Donna","family":"Catamero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia Bl\u00e1zquez","family":"Benito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Kobos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnob","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy","family":"Kruyswijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.soncn.2024.151621_bib0001","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.soncn.2024.151621_bib0002","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.soncn.2024.151621_bib0003","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2024.151621_bib0004","series-title":"Presented at the IMS Annual Meeting","article-title":"Cevostamab is efficacious and well tolerated in patients aged < 65 and \u226565 years with relapsed\/refractory multiple myeloma (RRMM)","author":"Krishnan","year":"2022"},{"issue":"6","key":"10.1016\/j.soncn.2024.151621_bib0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.soncn.2024.151621_bib0006","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood-2022-166494","article-title":"Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma","volume":"140","author":"Raje","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.soncn.2024.151621_bib0007","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2024.151621_bib0008","unstructured":"mSMART Stratification for Myeloma & Risk-Adapted Therapy. Accessed Aug 18, 2023. https:\/\/www.msmart.org\/"},{"key":"10.1016\/j.soncn.2024.151621_bib0009","unstructured":"Amorosi D. MD Anderson releases free CAR T-cell therapy toxicity grading and management app 2019. Accessed Aug 16, 2023. https:\/\/www.healio.com\/news\/hematology-oncology\/20190607\/md-anderson-releases-free-car-tcell-therapy-toxicity-grading-and-management-app"},{"issue":"3","key":"10.1016\/j.soncn.2024.151621_bib0010","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soncn.2024.151621_bib0011","series-title":"FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma","year":"2023"},{"key":"10.1016\/j.soncn.2024.151621_bib0012","series-title":"Abstract presented at: American Society of Clinical Oncology (ASCO) Annual Meeting","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a BCMA\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","author":"van de Donk","year":"2023"},{"key":"10.1016\/j.soncn.2024.151621_bib0013","series-title":"Prescribing information","year":"2022"},{"issue":"13","key":"10.1016\/j.soncn.2024.151621_bib0014","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.34756","article-title":"Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.soncn.2024.151621_bib0015","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.soncn.2024.151621_bib0016","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2024.151621_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719899897","article-title":"Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia","volume":"11","author":"Jain","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"10.1016\/j.soncn.2024.151621_bib0018","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41540-020-00145-7","article-title":"Mitigating the risk of cytokine release syndrome in a phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling","volume":"6","author":"Hosseini","year":"2020","journal-title":"NPJ Syst Biol Appl"},{"issue":"1","key":"10.1016\/j.soncn.2024.151621_bib0019","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2181016","article-title":"Strategies for clinical dose optimization of T cell-engaging therapies in oncology","volume":"15","author":"Ball","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.soncn.2024.151621_bib0020","series-title":"Managing cytokine release syndrome in relapsed\/refractory multiple myeloma: Experience with teclistamab in the MajesTEC-1 study presented at: 48th Annual Oncology Nursing Society Congress","author":"Catamero","year":"2023"},{"issue":"10","key":"10.1016\/j.soncn.2024.151621_bib0021","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.soncn.2024.151621_bib0022","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2024.151621_bib0023","series-title":"TECVAYLI prescribing information","year":"2023"},{"key":"10.1016\/j.soncn.2024.151621_bib0024","unstructured":"Janssen Biotech, Inc. 2022. TECVAYLI\u2122 Risk Evaluation and Mitigation Strategy (REMS). Accessed May 5, 2023. https:\/\/tecvaylirems.com\/#Main; 2023."},{"issue":"1","key":"10.1016\/j.soncn.2024.151621_bib0025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.soncn.2024.151621_bib0026","doi-asserted-by":"crossref","unstructured":"Raje NS, Anaissie E, Kumar SK, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9(2):e143-e161.","DOI":"10.1016\/S2352-3026(21)00283-0"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208124000603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208124000603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T10:13:22Z","timestamp":1733220802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208124000603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0749208124000603"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2024.151621","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nursing Considerations for Cytokine Release Syndrome in Relapsed\/Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2024.151621","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151621"}}